Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31679 in hypercholesterolemia and NAFLD
NCT05795517Phase 2Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK31679 in hypercholesterolemia, non-alcoholic fatty liver disease (NAFLD), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Apr 2023; status: completed.
02
Drugs
HSK31679
03
Conditions
hypercholesterolemianon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05795517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795517.